Share this video  

EAU 2022 | Updates in prostate cancer at EAU 2022

Bertrand Tombal, MD, PhD, Université catholique de Louvain, Louvain, Belgium, provides his highlights in the field of prostate cancer presented at the European Association of Urology (EAU) Meeting 2022, including developments in utilizing PSMA PET scans for diagnosing prostate cancer. Prof Tombal additionally comments on the Phase III PROfound (NCT02987543) and MAGNITUDE (NCT03748641) trials, which assessed olaparib and niraparib in combination with abiraterone acetate plus prednisone respectively. This interview took place at the EAU Meeting 2022.


Prof. Tombal reports the conflicts of interest:
Advisor and/or investigator for AstraZeneca, MSD, Pfizer, Astellas

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter